Raloxifene for the treatment and prevention of breast cancer?

Pappas, S G; Jordan, V C

Pappas, S G; Jordan, V C.

Pappas SG; Lynn Sage Breast Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, Olson Pavilion 8258, 303 E. Chicago Avenue, Chicago, IL 60611, USA.

Expert Rev Anticancer Ther ; 1(3): 334-40, 2001 Oct.

Article en En | MEDLINE | ID: mdl-12113100

ABSTRACT

ABSTRACT

Raloxifene is a member of a family of drugs known as selective estrogen receptor modulators (SERMs). Raloxifene is currently approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women. SERMs hold the potential to treat and prevent breast cancer, osteoporosis and coronary heart disease. Ongoing clinical trials are in place to address the role of raloxifene and SERMs in each of these areas. We review the pharmacology, clinical utility, safety and tolerability of raloxifene and speculate on what the future holds for SERMs and their use in breast cancer.

Asunto(s)

Neoplasias de la Mama/tratamiento farmacológico; Neoplasias de la Mama/prevención & control; Clorhidrato de Raloxifeno/uso terapéutico; Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico; Enfermedades Cardiovasculares/prevención & control; Femenino; Humanos; Lípidos/sangre; Osteoporosis/prevención & control; Clorhidrato de Raloxifeno/efectos adversos; Clorhidrato de Raloxifeno/farmacocinética; Factores de Riesgo; Moduladores Selectivos de los Receptores de Estrógeno/efectos adversos; Moduladores Selectivos de los Receptores de Estrógeno/farmacocinética; Útero/efectos de los fármacos

Search on Google

Imprimir

XML

PubMed Links

Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Clorhidrato de Raloxifeno / Moduladores Selectivos de los Receptores de Estrógeno Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2001 Tipo del documento: Article

Search on Google

Imprimir

XML

PubMed Links